

AUG 1 4 2002

TECH CENTER 1600/2900



## ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/049,847B

DATE: 07/24/2002

TIME: 14:12:07

Input Set : A:\102.166A-1.txt

Output Set: N:\CRF3\07242002\I049847B.raw

```
3 <110> APPLICANT: Bay, Sylvie
             Cantacuzene, Daniele
      5
             Leclerc, Claude
            Lo-Man, Richard
      8 <120> TITLE OF INVENTION: MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE,
            VACCINE COMPRISING THE SAME AND USE THEREOF
    11 <130> FILE REFERENCE: 102.166A-1
C--> 13 <140> CURRENT APPLICATION NUMBER: US/09/049,847B
C--> 14 <141> CURRENT FILING DATE: 1998-03-27
    16 <150> PRIOR APPLICATION NUMBER: US 09/049,847
    17 <151> PRIOR FILING DATE: 1998-03-27
    19 <150> PRIOR APPLICATION NUMBER: US 60/041,726
    20 <151> PRIOR FILING DATE: 1997-03-27
    22 <160> NUMBER OF SEQ ID NOS: 25
    24 <170> SOFTWARE: PatentIn version 3.1
    26 <210> SEQ ID NO: 1
    27 <211> LENGTH: 15
    28 <212> TYPE: PRT
    29 <213> ORGANISM: Clostridium tetani
    31 <400> SEQUENCE: 1
    33 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
    37 <210> SEQ ID NO: 2
    38 <211> LENGTH: 21
    39 <212> TYPE: PRT
    40 <213> ORGANISM: Clostridium tetani
    42 <400> SEQUENCE: 2
    44 Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
    45 1
                        5
                                                                 15
    48 Ala Ser' His Leu Glu
    49
                   20
    52 <210> SEQ ID NO: 3
    53 <211> LENGTH: 12
    54 <212> TYPE: PRT
    55 <213> ORGANISM: Clostridium tetani
    57 <400> SEQUENCE: 3
    59 Gly Gln Ile Gly Asn Asp Pro Asn Arg Asp Ile Leu
    60 1
                                            10
    63 <210> SEQ ID NO: 4
    64 <211> LENGTH: 13
    65 <212> TYPE: PRT
    66 <213> ORGANISM: Poliovirus
```

68 <400> SEQUENCE: 4

DATE: 07/24/2002

TIME: 14:12:07

Input Set : A:\102.166A-1.txt Output Set: N:\CRF3\07242002\I049847B.raw 70 Lys Leu Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp Thr 74 <210> SEQ ID NO: 5 75 <211> LENGTH: 15 76 <212> TYPE: PRT 77 <213> ORGANISM: Escherichia coli 79 <400> SEQUENCE: 5 81 Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser 85 <210> SEQ ID NO: 6 86 <211> LENGTH: 13 87 <212> TYPE: PRT 88 <213> ORGANISM: ARTIFICIAL SEQUENCE 90 <220> FEATURE: 91 <223> OTHER INFORMATION: Designed peptidic T-Helper Cell epitope that typically binds to a 92 plurality of human and murine Major Histocompatibility Complex . Class II molecules 93 95 <220> FEATURE: 96 <221> NAME/KEY: MISC\_FEATURE 97 <222> LOCATION: (1)..(1) 98 <223> OTHER INFORMATION: Xaa=D-Ala 101 <220> FEATURE: 102 <221> NAME/KEY: MISC\_FEATURE 103 <222> LOCATION: (3)..(3) 104 <223> OTHER INFORMATION: Xaa=L-cyclohexyl-Ala 107 <220> FEATURE: 108 <221> NAME/KEY: MISC\_FEATURE 109 <222> LOCATION: (13)..(13) 110 <223> OTHER INFORMATION: Xaa=D-Ala 113 <400> SEQUENCE: 6 W--> 115 Xaa Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Xaa 116 1 119 <210> SEQ ID NO: 7 120 <211> LENGTH: 10 121 <212> TYPE: PRT 122 <213> ORGANISM: Human papillomavirus type 16 124 <220> FEATURE: 125 <221> NAME/KEY: MISC\_FEATURE 126 <223> OTHER INFORMATION: HPV16 E7 PEPTIDE 129 <400> SEQUENCE: 7 131 Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn 132 1 135 <210> SEQ ID NO: 8 136 <211> LENGTH: 10 137 <212> TYPE: PRT 138 <213> ORGANISM: Human papillomavirus type 16 140 <220> FEATURE: 141 <221> NAME/KEY: MISC\_FEATURE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/049,847B

142 <223> OTHER INFORMATION: HPV16 E7 PEPTIDE

RAW SEQUENCE LISTING DATE: 07/24/2002 PATENT APPLICATION: US/09/049,847B TIME: 14:12:07

Input Set : A:\102.166A-1.txt

Output Set: N:\CRF3\07242002\I049847B.raw

145 <400> SEQUENCE: 8 147 Ala Glu Pro Asp Arg Ala His Tyr Asn Ile 151 <210> SEQ ID NO: 9 152 <211> LENGTH: 19 153 <212> TYPE: PRT 154 <213> ORGANISM: Human papillomavirus type 16 156 <220> FEATURE: 157 <221> NAME/KEY: MISC\_FEATURE 158 <223> OTHER INFORMATION: HPV 16 E7 PEPTIDE 161 <400> SEQUENCE: 9 163 Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Ile 164 1 167 Arg Thr Leu 171 <210> SEQ ID NO: 10 172 <211> LENGTH: 10 173 <212> TYPE: PRT 174 <213> ORGANISM: Human papillomavirus type 16 176 <220> FEATURE: 177 <221> NAME/KEY: MISC\_FEATURE 178 <223> OTHER INFORMATION: HPV16 E7 PEPTIDE 181 <400> SEQUENCE: 10 183 Gly Thr Leu Gly Ile Val Cys Pro Ile Cys 187 <210> SEQ ID NO: 11 188 <211> LENGTH: 13 189 <212> TYPE: PRT 190 <213> ORGANISM: Homo sapiens 192 <400> SEQUENCE: 11 194 Lys Leu Val Val Gly Ala Arg Gly Val Gly Lys Ser 195· 1 198 <210> SEQ ID NO: 12 199 <211> LENGTH: 15 200 <212> TYPE: PRT 201 <213> ORGANISM: Homo sapiens 203 <400> SEQUENCE: 12 205 His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys Gln Val Val 206 1 209 <210> SEQ ID NO: 13 210 <211> LENGTH: 15 211 <212> TYPE: PRT 212 <213> ORGANISM: Homo sapiens 214 <400> SEQUENCE: 13 216 Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val 217 1 10 220 <210> SEQ ID NO: 14 221 <211> LENGTH: 14

222 <212> TYPE: PRT

223 <213> ORGANISM: Homo sapiens

DATE: 07/24/2002

TIME: 14:12:07

Input Set : A:\102.166A-1.txt Output Set: N:\CRF3\07242002\I049847B.raw 225 <400> SEQUENCE: 14 227 Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val Thr Lys Ala Glu 228 1 231 <210> SEQ ID NO: 15 232 <211> LENGTH: 10 233 <212> TYPE: PRT 234 <213> ORGANISM: POLIOVIRUS 236 <400> SEQUENCE: 15 238 Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp 5 242 <210> SEQ ID NO: 16 243 <211> LENGTH: 14 244 <212> TYPE: PRT 245 <213> ORGANISM: Clostridium tetani 247 <400> SEQUENCE: 16 249 Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu 253 <210> SEQ ID NO: 17 254 <211> LENGTH: 11 255 <212> TYPE: PRT 256 <213> ORGANISM: ARTIFICIAL SEQUENCE 258 <220> FEATURE: 259 <223> OTHER INFORMATION: Designed synthetic linear glycopeptide containing a saccharidic 260 B-cell epitope and a CD4+ T-cell epitope able to induce anti-261 saccharidic antibodies 263 <400> SEQUENCE: 17 265 Ser Thr Thr Gly Gly Gly Gly Gly Lys Gly 266 1 269 <210> SEQ ID NO: 18 270 <211> LENGTH: 11 271 <212> TYPE: PRT 272 <213> ORGANISM: ARTIFICIAL SEQUENCE 274 <220> FEATURE: 275 <223> OTHER INFORMATION: Designed synthetic linear glycopeptide containing a saccharidic 276 B-cell epitope and a CD4+ T-cell epitope able to induce anti-277 saccharidic antibodies 279 <220> FEATURE: 280 <221> NAME/KEY: MISC\_FEATURE 281 <222> LOCATION: (1)..(1) 282 <223> OTHER INFORMATION: alpha-N-acetylgalactosamine (GalNAc)-Serine 285 <220> FEATURE: 286 <221> NAME/KEY: MISC\_FEATURE 287 <222> LOCATION: (2)..(3) 288 <223> OTHER INFORMATION: alpha-N-acetylgalactosamine (GalNAc)-Threonine 291 <400> SEQUENCE: 18 293 Ser Thr Thr Gly Gly Gly Gly Gly Lys Gly 294 1 10 297 <210> SEQ ID NO: 19

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/049,847B

298 <211> LENGTH: 11

DATE: 07/24/2002

TIME: 14:12:07

Input Set : A:\102.166A-1.txt Output Set: N:\CRF3\07242002\I049847B.raw 299 <212> TYPE: PRT 300 <213> ORGANISM: ARTIFICIAL SEQUENCE 302 <220> FEATURE: 303 <223> OTHER INFORMATION: Designed synthetic linear glycopeptide containing a saccharidic 304 B-cell epitope and a CD4+ T-cell epitope able to induce anti-305 saccharidic antibodies 307 <220> FEATURE: 308 <221> NAME/KEY: MISC\_FEATURE 309 <222> LOCATION: (1)..(1) 310 <223> OTHER INFORMATION: alpha-N-acetylgalactosamine (GalNAc)-Serine 313 <220> FEATURE: 314 <221> NAME/KEY: MISC\_FEATURE 315 <222> LOCATION: (2)..(3) 316 <223> OTHER INFORMATION: alpha-N-acetylgalactosamine (GalNAc)-Threonine 319 <220> FEATURE: 320 <221> NAME/KEY: MISC\_FEATURE 321 <222> LOCATION: (10)..(10) 322 <223> OTHER INFORMATION: Biotinylated 325 <400> SEOUENCE: 19 327 Ser Thr Thr Gly Gly Gly Gly Gly Lys Gly 328 1 331 <210> SEQ ID NO: 20 332 <211> LENGTH: 11 333 <212> TYPE: PRT 334 <213> ORGANISM: ARTIFICIAL SEQUENCE 336 <220> FEATURE: 337 <223> OTHER INFORMATION: Designed synthetic linear glycopeptide containing a saccharidic 338 B-cell epitope and a CD4+ T-cell epitope able to induce anti-339 saccharidic antibodies 341 <220> FEATURE: 342 <221> NAME/KEY: MISC\_FEATURE 343 <222> LOCATION: (7)..(8) 344 <223> OTHER INFORMATION: alpha-N-acetylgalactosamine (GalNAc)-Threonine 347 <400> SEQUENCE: 20 349 Lys Gly Gly Gly Ser Thr Thr Gly Gly Gly 350 1 10 353 <210> SEQ ID NO: 21 354'<211> LENGTH: 14 355 <212> TYPE: PRT 356 <213> ORGANISM: ARTIFICIAL SEQUENCE 358 <220> FEATURE: 359 <223> OTHER INFORMATION: Designed synthetic linear glycopeptide containing a saccharidic 360 B-cell epitope and a CD4+ T-cell epitope able to induce anti-361 saccharidic antibodies 363 <220> FEATURE: 364 <221> NAME/KEY: MISC\_FEATURE 365 <222> LOCATION: (1)..(1) 366 <223> OTHER INFORMATION: alpha-N-acetylgalactosamine (GalNAc)-Serine

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/049,847B

369 <400> SEQUENCE: 21

RAW SEQUENCE LISTING ERROR SUMMARY PATENT APPLICATION: US/09/049,847B

DATE: 07/24/2002 TIME: 14:12:08

Input Set : A:\102.166A-1.txt

Output Set: N:\CRF3\07242002\I049847B.raw

## Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:6; Xaa Pos. 1,3,13

VERIFICATION SUMMARY

DATE: 07/24/2002

PATENT APPLICATION: US/09/049,847B

TIME: 14:12:08

Input Set : A:\102.166A-1.txt

Output Set: N:\CRF3\07242002\I049847B.raw

L:13 M:270 C: Current Application Number differs, Replaced Current Application Number

L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:115 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0